Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
This adjuvant does not impact immune competence of non-human primates and mice, and repeated administration of the adjuvant does not show renal or hepatic toxicity. Formulation of monoclonal antibodies with the immunoregulatory adjuvant, OPLS, was found to be safe and effective at mitigating immunogenicity.
Authors
- Nhan H. Nguyen (ORCID: https://orcid.org/0000-0001-8998-0145)
- Donald E. Mager (ORCID: https://orcid.org/0000-0002-4848-0440)
- Brooke Grasperge (ORCID: https://orcid.org/0000-0002-1262-6217)
- Manali Indravadan Patel (ORCID: https://orcid.org/0000-0002-9943-5762)
- Sathy V. Balu‐Iyer (ORCID: https://orcid.org/0000-0002-0569-2865)
- Robert M. Straubinger (ORCID: https://orcid.org/0000-0003-0870-9236)
- Krithika A. Shetty (ORCID: https://orcid.org/0000-0002-1332-8502)
- Nicole L. Jarvi (ORCID: https://orcid.org/0000-0001-6146-0324)
Institutions
- Tulane University (US)
- AngioDynamics (United States) (US)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1496169
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- University at Buffalo